Publication details

Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy

Authors

RŮŽEK Lukáš KONECNY Tomas SOUČEK Filip KONECNY Dana MACH Lukáš OMMEN Steve R. KOPECKY Stephen L. NISHIMURA Rick A.

Year of publication 2015
Type Article in Periodical
Magazine / Source American Journal of Cardiology
MU Faculty or unit

Faculty of Medicine

Citation
Web http://www.ajconline.org/article/S0002-9149(15)01346-6/abstract
Doi http://dx.doi.org/10.1016/j.amjcard.2015.05.022
Field Cardiovascular diseases incl. cardiosurgery
Keywords Hypertrophic cardiomyopathy; male sexual dysfunction; phosphodiesterase type 5; sildenafil
Description The prevalence of sexual dysfunction (SD) in men with hypertrophic cardiomyopathy (HC) remains unknown, yet its clinical relevance may be high given that its treatment- phosphodiesterase 5 inhibitors (PDE5i)-can increase the left ventricular outflow tract pressure gradient. In this retrospective study, we evaluated the medical records of consecutively seen men with HC for the evidence of SD (defined as SD diagnosis noted in the medical record, the use of medications unique for SD, or SD reported by the patient on a routine clinical questionnaire). Of the 283 consecutively seen men with HC (mean age 52.9 +/- 14.1 years), 63 patients (22%) with SD were identified. Of those with SD, 38% were recorded as regularly using PDE5i. In conclusion, SD and the use of PDE5i present a relatively common occurrence in men with HC, and further studies are needed to develop an evidence-guided algorithm for safe implementation of SD therapies in this most common inherited cardiomyopathy.

You are running an old browser version. We recommend updating your browser to its latest version.

More info